FAQ on HeartBeam Inc. and AccurKardia's Partnership for Remote ECG Monitoring

What is the purpose of the partnership between HeartBeam Inc. and AccurKardia?

The partnership aims to integrate AccurKardia’s FDA-cleared ECG analysis software, AccurECG, into HeartBeam’s compact, cable-free 3D ECG device to enhance remote cardiac monitoring and diagnosis.

Why is this partnership significant?

This collaboration is significant because it combines HeartBeam’s innovative 3D ECG technology with AccurKardia’s advanced ECG analysis software to improve access to cardiac care and accelerate diagnosis.

How does HeartBeam’s device work?

HeartBeam’s device is a cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions, designed for use in portable devices to deliver actionable heart intelligence remotely.

Who will benefit from this partnership?

Patients requiring remote cardiac monitoring and physicians seeking to identify cardiac health trends and acute conditions outside of medical facilities will benefit from this partnership.

What are the expected outcomes of this collaboration?

The collaboration is expected to streamline HeartBeam’s product development and expand the reach of remote cardiac monitoring solutions, enhancing the efficiency of cardiac care.

Where can I find more information about HeartBeam Inc.?

More information about HeartBeam Inc. can be found on their website at www.HeartBeam.com.

Where can I view the full press release about this partnership?

The full press release can be viewed at https://ibn.fm/uRh5i.

What patents does HeartBeam hold?

HeartBeam holds 13 U.S. and 4 international-issued patents related to technology enablement for their cardiac care innovations.